Cripto-1: an extracellular protein – connecting the sequestered biological dots

Abstract Cripto-1 (CR-1) is a multifunctional embryonic protein that is re-expressed during inflammation, wound repair, and malignant transformation. CR-1 can function either as a tethered co-receptor or shed as a free ligand underpinning its flexible role in cell physiology. CR-1 has been shown to mediate cell growth, migration, invasion, and induce epithelial to mesenchymal transition (EMT). The main signaling pathways mediating CR-1 effects include Nodal-dependent (Smad2/3) and Nodal-independent (Src/p44/42/Akt) signaling transduction pathways. In addition, there are several naturally occurring binding partner proteins (BPPs) for CR-1 that can either agonize or antagonize its bioactivity. We will review the collective role of CR-1 as an extracellular protein, discuss caveats to consider in developing a quantitation assay, define possible mechanistic avenues applicable for drug discovery, and report on our experimental approaches to overcome these problematic issues.

[1]  C. Toulas,et al.  Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response , 2015, PloS one.

[2]  A. Caporale,et al.  Conformational features and binding affinities to Cripto, ALK7 and ALK4 of Nodal synthetic fragments , 2015, Journal of peptide science : an official publication of the European Peptide Society.

[3]  M. Todaro,et al.  Dynamic regulation of the cancer stem cell compartment by Cripto-1 in colorectal cancer , 2015, Cell Death and Differentiation.

[4]  Toshiro Sato,et al.  Suppressing TGFβ signaling in regenerating epithelia in an inflammatory microenvironment is sufficient to cause invasive intestinal cancer. , 2015, Cancer research.

[5]  K. Finegan,et al.  ERK5 is a critical mediator of inflammation-driven cancer. , 2015, Cancer research.

[6]  S. Sen,et al.  Autoregulation and Heterogeneity in Expression of Human Cripto-1 , 2015, PloS one.

[7]  D. Salomon,et al.  The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition. , 2014, Seminars in cancer biology.

[8]  J. Medema,et al.  Cancer stem cells – important players in tumor therapy resistance , 2014, The FEBS journal.

[9]  R. Laursen,et al.  Cripto‐1 Expression in Glioblastoma Multiforme , 2014, Brain pathology.

[10]  J. Ingle,et al.  Inhibition of Cdk2 kinase activity selectively targets the CD44+/CD24−/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells , 2014, International journal of oncology.

[11]  G. Wahl,et al.  CRIPTO/GRP78 Signaling Maintains Fetal and Adult Mammary Stem Cells Ex Vivo , 2014, Stem cell reports.

[12]  M. Hendrix,et al.  Age-Dependent Association between Protein Expression of the Embryonic Stem Cell Marker Cripto-1 and Survival of Glioblastoma Patients. , 2013, Translational oncology.

[13]  E. Elinav,et al.  Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms , 2013, Nature Reviews Cancer.

[14]  M. Hendrix,et al.  The significance of a Cripto-1-positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics , 2013, Cell cycle.

[15]  Shutang Zhou,et al.  Radiation-induced lung injury is mitigated by blockade of gastrin-releasing peptide. , 2013, The American journal of pathology.

[16]  M. Sales,et al.  Autoantibodies against Muscarinic Receptors in Breast Cancer: Their Role in Tumor Angiogenesis , 2013, PloS one.

[17]  Ian Krop,et al.  Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors , 2013, Clinical Cancer Research.

[18]  K. Camphausen,et al.  Aryl hydrocarbon receptor-induced adrenomedullin mediates cigarette smoke carcinogenicity in humans and mice. , 2012, Cancer research.

[19]  P. Carmeliet,et al.  Cripto regulates skeletal muscle regeneration and modulates satellite cell determination by antagonizing myostatin , 2012, Proceedings of the National Academy of Sciences.

[20]  W. Vale,et al.  Cripto/GRP78 modulation of the TGF‐β pathway in development and oncogenesis , 2012, FEBS letters.

[21]  M. Maroun,et al.  Serologic laboratory findings in malignancy. , 2011, Rheumatic diseases clinics of North America.

[22]  C. Bianco,et al.  Targeting the embryonic gene Cripto-1 in cancer and beyond , 2010, Expert opinion on therapeutic patents.

[23]  M. Hendrix,et al.  Cripto‐1 Is a Cell Surface Marker for a Tumorigenic, Undifferentiated Subpopulation in Human Embryonal Carcinoma Cells , 2010, Stem cells.

[24]  A. Arai,et al.  Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse embryonic stem cells. , 2009, The American journal of pathology.

[25]  E. Danen,et al.  The cancer stem cell microenvironment and anti-cancer therapy , 2009, International journal of radiation biology.

[26]  P. Carmeliet,et al.  G Protein–Coupled Receptor APJ and Its Ligand Apelin Act Downstream of Cripto to Specify Embryonic Stem Cells Toward the Cardiac Lineage Through Extracellular Signal-Regulated Kinase/p70S6 Kinase Signaling Pathway , 2009, Circulation research.

[27]  M. Hendrix,et al.  Potential for Cripto-1 in defining stem cell-like characteristics in human malignant melanoma , 2008, Cell cycle.

[28]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[29]  C. Bianco,et al.  Requirement of Glycosylphosphatidylinositol Anchor of Cripto-1 for trans Activity as a Nodal Co-receptor* , 2007, Journal of Biological Chemistry.

[30]  R. Martínez-Murillo,et al.  Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells. , 2007, Histology and histopathology.

[31]  C. Ibáñez,et al.  Distinct and cooperative roles of mammalian Vg1 homologs GDF1 and GDF3 during early embryonic development. , 2007, Developmental biology.

[32]  A Murray,et al.  Autoantibodies in lung cancer: possibilities for early detection and subsequent cure , 2007, Thorax.

[33]  J. Robertson,et al.  Autoantibodies in breast cancer: their use as an aid to early diagnosis. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  M. Shen.  Nodal signaling: developmental roles and regulation , 2007, Development.

[35]  D. Salomon,et al.  Early dysregulation of cripto-1 and immunomodulatory genes in the cerebral cortex in a macaque model of neuroAIDS , 2006, Neuroscience Letters.

[36]  S. Pizzo,et al.  Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. , 2006, Cancer research.

[37]  W. Vale,et al.  Cripto Binds Transforming Growth Factor β (TGF-β) and Inhibits TGF-β Signaling , 2006, Molecular and Cellular Biology.

[38]  A. Ebert,et al.  Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma , 2005, Oncogene.

[39]  A. Ebert,et al.  Role of human cripto-1 in tumor angiogenesis. , 2005, Journal of the National Cancer Institute.

[40]  N. Normanno,et al.  Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV‐Cripto‐1 transgenic mice , 2004, Journal of cellular physiology.

[41]  T. Moody,et al.  Identification of vasoactive nonpeptidic positive and negative modulators of adrenomedullin using a neutralizing antibody-based screening strategy. , 2004, Endocrinology.

[42]  Michael M Shen,et al.  Two Modes by which Lefty Proteins Inhibit Nodal Signaling , 2004, Current Biology.

[43]  A. Ebert,et al.  Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells. , 2001, Experimental cell research.

[44]  P. Zipfel,et al.  Complement Factor H Is a Serum-binding Protein for Adrenomedullin, and the Resulting Complex Modulates the Bioactivities of Both Partners* , 2001, The Journal of Biological Chemistry.

[45]  C. Bianco,et al.  Cripto: a novel epidermal growth factor (EGF)‐related peptide in mammary gland development and neoplasia , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[46]  R. J. Alexander,et al.  Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel diseas , 1995, Digestive Diseases and Sciences.

[47]  T. Iglesias,et al.  Thyroid hormone regulates stromelysin expression, protease secretion and the morphogenetic potential of normal polarized mammary epithelial cells. , 1995, The EMBO journal.

[48]  H. Schwarz,et al.  Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion , 1992, Cell.

[49]  B. Groner,et al.  New mammary epithelial and fibroblastic cell clones in coculture form structures competent to differentiate functionally , 1989, The Journal of cell biology.

[50]  E. Engvall,et al.  Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. , 1971, Immunochemistry.

[51]  B. van Weemen,et al.  Immunoassay using antigen—enzyme conjugates , 1971, FEBS letters.

[52]  A. Mantovani,et al.  Cancer: Inflaming metastasis , 2008, Nature.

[53]  D. Clemmons.  Quantitative measurement of IGF-I and its use in diagnosing and monitoring treatment of disorders of growth hormone secretion. , 2005, Endocrine development.

[54]  Dr Ferdiye Taner,et al.  The enzyme-linked immunosorbent assay (ELISA). , 1976, Bulletin of the World Health Organization.

[55]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.